Novo Nordisk’s interest in exploring childhood and adolescent obesity pilots in India is not only a development in the market for weight-management medicines. It also raises a wider question about how India will decide which chronic diseases deserve public funding, how early intervention should be organised and whether newer treatments can move beyond a small privately paying population.
In an interaction with Business Standard, Emil Kongshoej Larsen, executive vice-president for international operations at Novo Nordisk, said the Danish drugmaker hoped to explore pilots focused on childhood and adolescent obesity. The company believes early intervention could reduce the likelihood that children and adolescents with obesity develop the condition as adults and later face diseases such as diabetes and cardiovascular ailments.
Larsen did not announce a government programme or provide details of a confirmed pilot. He said Novo Nordisk hoped to find pilots that could help “bend the obesity curves for the coming generations”. The statement therefore points to a possible direction of engagement rather than an established public-sector intervention.
That distinction matters because the proposal sits within a health system where access to chronic disease treatment is uneven and public financing remains selective. Larsen said India was showing positive developments in public-sector involvement, particularly in diabetes, and suggested that this could eventually extend to newer treatments such as glucagon-like peptide-1, or GLP-1, medicines. He also called for a larger role for public funding in serious chronic diseases, arguing that the immediate expenditure should be viewed as an investment for society.
The central challenge is not simply whether a new medicine is available. It is whether the health system can identify people who may benefit, assess them consistently, pay for long-term treatment, monitor outcomes and prevent access from being concentrated among households able to absorb recurring costs.
The affordability gap in GLP-1 treatment
The Indian market for semaglutide, the molecule behind Novo Nordisk’s Ozempic and Wegovy, has expanded since Wegovy was launched in June 2025 and Ozempic in December of the same year. The market changed again after semaglutide’s patent expired in March 2026, allowing Indian drugmakers to introduce lower-priced versions.
Novo Nordisk has also reduced its prices as competition has intensified. From April, the starting doses of Ozempic and Wegovy were priced at ₹1,415 a week, or ₹5,660 a month. Business Standard reported that this represented price reductions of 36 per cent for Ozempic and 48 per cent for Wegovy.
Those reductions may improve access, but a monthly cost of ₹5,660 remains a substantial recurring expense for many households. The figure also represents only the medicine’s listed cost. A treatment pathway may involve medical consultations, diagnosis, follow-up, monitoring and management of side effects. The supplied report does not establish how these additional costs are distributed across patients, nor does it provide evidence of public reimbursement for semaglutide in India.
Larsen said only a fraction of Indians who could benefit from semaglutide currently receive it, even as affordability improves. His assessment points to a market that is expanding but remains at an early stage of adoption. It also reveals the limits of interpreting product launches as equivalent to healthcare access. A medicine can be legally available and still remain outside the practical reach of most eligible patients.
The public-sector question
Novo Nordisk’s argument for a greater public role shifts the debate from product availability to the design of chronic disease financing. Larsen said the Indian government and states were “stepping up”, particularly in diabetes, and described this as a sensible first move towards considering newer modalities such as GLP-1 medicines for more patients.
The report does not identify a specific central or state scheme that currently funds GLP-1 treatment. It also does not establish whether any government has agreed to the childhood obesity pilots discussed by the company. What it does show is that the commercial expansion of obesity medicines is increasingly being linked to public policy questions around prevention, long-term disease costs and treatment eligibility.
This is especially significant because diabetes already creates a large treatment burden. The Indian Council of Medical Research–India Diabetes study estimated that 101 million people in India were living with diabetes. Larsen contrasted India’s position with China, where the International Diabetes Federation estimated around 148 million adults had diabetes in 2024. He said the two countries shared large unmet medical needs but differed in access, with a larger proportion of patients in China receiving reimbursed treatment.
The comparison, as presented in the report, is not a direct assessment of the two countries’ health systems. It does, however, highlight the institutional issue facing India: the scale of chronic disease is large, while the mechanisms that determine who receives newer, high-cost treatment are still developing.
Why childhood intervention changes the policy calculation
A childhood obesity pilot would also be different from a conventional medicine launch because it would require coordination beyond prescribing. Any serious public-sector programme would need a method for identifying children and adolescents, clinical criteria for intervention, trained healthcare providers, follow-up systems and safeguards around treatment decisions. The supplied material does not specify how a pilot would be designed, who would fund it or which public institutions would implement it.
The company’s rationale is that obesity during childhood or adolescence may be associated with later adult obesity and diseases including diabetes and cardiovascular conditions. That makes the proposal part of a prevention argument: spending earlier could, in theory, reduce later health burdens. But the report does not provide an economic evaluation or outcome data for a proposed Indian pilot. The claim remains a rationale offered by the company, not evidence that a specific programme would deliver those results.
The institutional setting would also matter. The company is asking for a wider public-sector role while simultaneously seeking to expand its own medicines and differentiate them from lower-priced alternatives. That does not invalidate the public-health issue, but it means policy decisions would need to distinguish between the need for obesity and diabetes care and the commercial interests of individual manufacturers.
Novo Nordisk is seeking to differentiate its products as Indian companies enter the semaglutide market. Vikrant Shrotriya, managing director of Novo Nordisk India, said semaglutide could be produced through recombinant deoxyribonucleic acid technology or chemical synthesis, and that Novo used the former. He said differences could also arise in purification, formulation, fill-and-finish and delivery devices. The company is educating doctors about these manufacturing processes and product characteristics.
For patients and public agencies, the practical question is not only how a medicine is made but how quality, effectiveness, safety, price and continuity of supply will be assessed. The report records the company’s position on manufacturing and quality, but does not independently compare competing products or establish whether one production method produces better clinical outcomes.
A market moving beyond one medicine
Novo Nordisk is also developing a broader obesity-treatment pipeline. Larsen said the company was pursuing higher doses of semaglutide, including 2 milligrams for diabetes and 7.2 milligrams for obesity. It is also combining amylin with semaglutide, an approach that he said had produced average weight loss of around 23 per cent in some trial readouts and up to 25 per cent among women, alongside improved blood sugar control.
The company is working on zenagamtide, described by Larsen as a single molecule combining GLP-1 and amylin that can also be administered orally. He said such therapies could potentially reach markets towards the end of the decade. These are development-stage claims and timelines, not confirmed Indian launches.
The direction of research is also changing from treating obesity as one uniform condition. Larsen said some patients may need very high levels of weight loss, while others may require treatment directed at specific risks or accompanying conditions such as liver disease. Convenience, tolerability and side-effect profiles are expected by the company to become increasingly important alongside efficacy.
Oral medicines are part of that strategy. Larsen said patient research showed that many people with obesity preferred tablets to injections. Novo Nordisk has begun rolling out oral semaglutide internationally and has said it plans to launch it in more than 20 countries before the end of next year. He described India as a “natural progression” for the oral formulation but did not give a launch timeline.
The sequence is important for India. The immediate opportunity, according to Larsen, is to expand access to existing semaglutide treatment. Higher doses and an oral version could follow for patients requiring additional control or particular cardiovascular benefits. The report does not establish when, or under what regulatory and reimbursement conditions, those products could become available in India.
Supply, access and the limits of expansion
Larsen said Novo Nordisk did not expect supply to become a constraint as the Indian market expanded. He said the company would “100 per cent supply the future needs” across GLP-1 medicines, insulin and other areas in which it operates. He pointed to Novo’s long presence in India’s insulin market and the launch of once-weekly insulin in the country as evidence of its approach.
Supply assurance addresses one possible bottleneck, but it does not resolve the wider access problem. Treatment can remain limited by price, diagnosis, medical capacity, public funding and the ability of patients to continue therapy. Novo’s stated commitment to offering innovative products as well as more affordable treatments is a company position; the report does not provide details of future prices, procurement arrangements or public-sector contracts.
The larger urban and public-health question is how India’s cities and states will manage chronic diseases that are shaped by long-term patterns of food, activity, income, healthcare access and the physical environment. The report does not present evidence linking obesity trends to particular urban forms or municipal conditions, so those connections cannot be established from this material alone. It does show, however, that treatment access is becoming a question of public systems rather than only private consumption.
The proposed childhood obesity pilots remain an early-stage possibility. The evidence currently confirms interest from Novo Nordisk, a growing and increasingly competitive semaglutide market, falling starting prices, a large diabetes burden and a company push for greater public funding. It does not yet confirm a government-backed pilot, a reimbursement decision, an oral semaglutide launch date or a model for delivering obesity treatment at scale. Those will be the milestones that determine whether India’s obesity discussion moves from commercial expansion to durable public-health provision.
